Zhenchuan Tablets Veterinary Grade API is received as a controlled-particle-size bulk powder in multi-walled paper sacks with polyethylene liners, and each incoming lot is released against a certificate of analysis covering assay, related substances, loss on drying, residual solvents, and particle size distribution. In swine in-feed medication, the API is first screened through a 1,000 µm vibratory sieve and introduced into a 2,000 L horizontal ribbon blender at a fill volume not exceeding 70% of shell capacity. The geometric dilution sequence begins with a 1:3 w/w pre-blend of API and lactose monohydrate, followed by a 1:10 w/w pre-blend with wheat middlings, after which the remaining carrier is charged over 15 min while the agitator operates at 35 rpm. Blend uniformity is sampled at 10 stratified points using a point thief; the batch is acceptable only when the relative standard deviation of assay values is ≤ 5.0% and individual samples fall between 90.0% and 110.0% of label claim under ISO 6497:2014 and VICH GL18(R2). The addition ratio is set by the final complete-feed concentration: when a finished feed requires 200 ppm API, the intermediate premix is manufactured at 50 g/kg active content, and 4.0 kg of the premix is dispersed per 1,000 kg of complete feed. For lower target concentrations, a 10 g/kg premix is produced to maintain a final weigh accuracy above 0.1 kg per batch and to avoid weigh-cell resolution errors at the farm feed mill. Production is conducted in a dedicated area under negative differential pressure of −5 Pa to −15 Pa relative to adjacent corridors, with dust collection routed through high-efficiency particulate air filters before discharge. Cross-contamination limits are calculated from the carryover criterion of 1% of the lowest acceptable daily intake; after any batch containing the API, the line is cleaned and swab samples are tested by liquid chromatography with a limit of quantification not exceeding 1 ng/cm². The API is not exposed to direct steam injection during carrier conditioning, and residual moisture in the finished premix is controlled at ≤ 9.0% w/w to limit hydrolytic degradation. Terminal presentations are 1 kg and 5 kg aluminium-foil sachets, 25 kg paper sacks with polyethylene inner liners, and 500 kg woven polypropylene bulk bags for licensed feed-mill receiving systems.

What Happens When the Same API Is Formulated into a Water-Soluble Granule for Poultry Drinking Lines?

Water-soluble granule production shifts the formulation challenge from dry blend homogeneity to dissolution kinetics, hygroscopicity, and content uniformity when the finished product is administered through proportioned drinking-line medicators. The API is co-milled with anhydrous sorbitol and polyvinylpyrrolidone K-30 to achieve a D90 ≤ 125 µm, then granulated in a top-spray fluid bed using an 8% w/w aqueous povidone solution as binder. Inlet air temperature is maintained at 72°C, product temperature at 36°C, and the spray rate is 120 g/min per 1.0 m² distributor plate. The granule fraction between 250 µm and 1,400 µm is retained as the finished product; fines below 125 µm are recycled into the binder feed, and the dried granule is conditioned to a moisture content of 1.5–2.5% w/w before packaging. The formulation addition ratio is 20.0 g API per 100.0 g granule, equivalent to 20.0% w/w active content. A final drinking water concentration of 100 mg/L is achieved by dissolving 500 g of granule in 1,000 L of medicated drinking water; the medicated solution is prepared daily and must be used within 24 h unless extended chemical stability is demonstrated. Dissolution testing at 37°C in 900 mL purified water with paddle speed 50 rpm requires release of not less than 85% of the labelled API within 15 min for the 500 g product. Granule bulk density is controlled between 0.48 g/mL and 0.62 g/mL to ensure that the sachet fill weight delivers the stated active content without excessive pack volume. Compliance for this application references EU Regulation 2019/4 for medicated feed, 21 CFR 225.120 for production and sanitation, WHO GMP Annex 5 for non-sterile liquids, USP <711> for dissolution characterization, and VICH GL2 for stability-indicating analytical procedures. The dissolved API is incompatible with highly alkaline chlorine stock solutions used in some poultry house water lines; therefore, the product must not be mixed directly with concentrated sodium hypochlorite solution above 50 ppm free chlorine. Terminal products are 100 g, 500 g, and 1,000 g polyethylene-lined aluminium sachets in cartons, and 5 kg high-density polyethylene tubs for larger broiler and layer operations.

Terminal Sterilization and Particle Burden Control in Parenteral Solutions for Cattle and Swine

Parenteral manufacturing for multi-species injectables begins with water for injection generated by hot-loop distillation at 80°C and held under nitrogen pressure of 0.2 bar in 316L stainless steel storage. The API is dissolved in 300 mL of propylene glycol per 1,000 mL final solution, then combined with benzyl alcohol 1.5% w/v as preservative and water for injection to volume. The batch is passed through a 0.22 µm polyvinylidene difluoride filter at 18 L/h per 0.1 m² filter area and filled into 50 mL or 100 mL Type II amber glass vials under laminar air flow. The addition ratio for a common injectable strength is 100 mg API per 1.0 mL of sterile solution, stated as 100 mg/mL. Batch calculations are adjusted by the assay value and loss on drying of the API lot; for example, a lot with 99.2% potency and 0.8% moisture requires a corrected charge of 101.0 g per 1.0 L. Sterility assurance is based on moist heat terminal sterilization at 121°C for 15 min with an F0 value ≥ 12 min; the load pattern is validated with Geobacillus stearothermophilus biological indicators. The specification includes pH 4.5–6.5, osmolality 280–320 mOsm/kg, and bacterial endotoxin ≤ 0.5 EU/mg. Regulatory compliance is anchored to 21 CFR 210 and 211, EU GMP Annex 1 for terminally sterilized products, USP <1> for injections, USP <788> for particulate matter, USP <790> for visible particulates, Ph.Eur. 2.9.19 for sub-visible particles, and VICH GL18 for impurities in new veterinary products. The API must not be compounded with dextrose-containing vehicles before sterilization because reducing sugars accelerate degradation; if a dextrose-based infusion is prescribed, the API is administered separately and flushed with 0.9% sodium chloride. Finished presentations are 50 mL and 100 mL injection vials with bromobutyl rubber stoppers and flip-off seals, packed in partitioned cartons. The product is labelled for veterinary use only with maximum single-dose volumes of 10 mL for swine and 15 mL for cattle based on tissue tolerance studies.

Low-dose tablet production for companion animal applications requires the API to be milled to D90 ≤ 75 µm and pre-dispersed with a hydrophobic anti-static agent to prevent segregation during high-speed direct compression. The formulation is built around microcrystalline cellulose PH-102 at 70% w/w, sodium starch glycolate at 5% w/w, povidone K-30 at 5% w/w, colloidal silicon dioxide at 1% w/w, and magnesium stearate at 0.5% w/w; the API is incorporated at 4.0% w/w for a 10 mg tablet with a core weight of 250 mg. Tableting is carried out on a rotary press with a precompression force of 8 kN, main compression force of 16 kN, and turret speed of 35 rpm; tablet hardness is maintained at 5–15 kp, friability below 0.5% after 4 min in a USP friabilator, and disintegration time ≤ 15 min in purified water at 37°C. The addition ratio for compounded capsules is 5.56% w/w when a size 3 hard gelatin capsule is filled to 180 mg and labelled to deliver 10 mg API per capsule. For tablet cores containing 20 mg API, the API fraction is increased to 8.0% w/w and the core weight is held at 250 mg; direct compression remains preferred if the API compactability stays within the accepted tabletability range. Blends are sampled at 10 points and tested for uniformity according to USP <905> Uniformity of Dosage Units, with acceptance value ≤ 15.0. Reference standards include USP <711> Dissolution, USP <701> Disintegration, USP <1217> Tablet Breaking Force, and Ph.Eur. 2.9.40 Uniformity of Content. Moisture control is critical: the pre-blend is conditioned at 20–25°C and 30–40% relative humidity, and direct compression is halted if equilibrium moisture rises above 2.0% w/w because the API exhibits increased sticking to steel punches at higher moisture. Batch-to-batch variance in API particle size is controlled within D90 50–90 µm; oversized particles create top-to-bottom segregation in the feed frame and require a 60 s mixer scoop after transfer. Terminal products are 10 mg, 20 mg, and 40 mg tablets in polyvinyl chloride/aluminium blisters, and 10 mg capsules in high-density polyethylene bottles with desiccant canisters.

If the API Is Delivered Through Extruded Aquaculture Feeds, Thermal History Determines Recovery

Thermal stress in extruded aquafeed lines is not a single-point concern but a cumulative exposure across preconditioning, high-shear cooking, and post-extrusion drying; each stage must be mapped against the degradation kinetics of the API. The medicated feed is produced by first adsorbing the API onto precipitated silica at a 1:9 API-to-carrier ratio, then blending this adsorbed intermediate with fish meal, soybean meal, wheat gluten, and fish oil in a 500 kg twin-shaft paddle mixer to form a coating premix containing 20 g/kg active ingredient. The coated premix is applied after the extrusion step in a vacuum coater at 0.8 bar negative pressure and 60°C temperature, preserving the active fraction from barrel heat. The addition ratio in the final extruded pellet is 10 kg of the 20 g/kg coating premix per 1,000 kg of uncoated pellets, yielding 200 mg/kg active in the finished medicated feed. If the target species requires 100 mg/kg, the coating premix is reduced to 5 kg/t or diluted with fish oil prior to vacuum coating. Compliance for aquaculture feed is aligned with 21 CFR 225.120 and 21 CFR 558 where the product is considered a medicated feed, EU Regulation 2019/4 for medicated feed, Codex Alimentarius CAC/RCP 52-2003 for fish and fishery products, and VICH GL18 for residue and impurity evaluation. Extrusion is conducted on a twin-screw extruder with an L/D ratio of 22:1, barrel zones set at 80°C, 95°C, and 110°C, screw speed 350 rpm, and die pressure below 60 bar. The moisture of the uncoated pellet is dried to 8–10% w/w in a fluidized bed before the medicated oil coating because residual moisture above 12% reduces coating adhesion and increases lipid oxidation. The API must not be added to the preconditioner or the extruder barrel; published data for this specific configuration in extruded aquatic species diets is limited, so stability on the hot pellet surface should be confirmed by pilot-scale recovery studies before registration. Terminal products are 2 mm and 4 mm sinking pellets in 5 kg vacuum-sealed bags for freshwater fish and shrimp production systems, and 25 kg laminated sacks for cage aquaculture.

Liquid Drench and Rumen Delivery Systems Require Buffered Solvent Matrices

Aqueous drench formulations are compounded in jacketed 316L stainless steel vessels equipped with a high-shear rotor-stator mixer operating at 3,000 rpm. The API is first dissolved in a co-solvent blend of propylene glycol 30% v/v and polysorbate 80 2.0% v/v, then diluted with phosphate-buffered purified water to 1.0 L final volume. The solution is adjusted to pH 5.0–5.5 with 0.1 M sodium hydroxide or hydrochloric acid, and benzyl alcohol is added as a preservative at 1.5% w/v. The batch is recirculated through a 10 µm polypropylene filter for 15 min to remove undissolved particulates and to achieve a clear formulation. The addition ratio for a typical ruminant oral drench is 50 mg API per 1.0 mL of solution, equivalent to 5.0% w/v. A 20 mg/mL oral liquid is manufactured by reducing the API charge to 20.0 g/L and increasing the aqueous phase proportion to maintain total volume. Regulatory references for oral liquids in food-producing ruminants include EU GMP Annex 5 for non-sterile liquids, 21 CFR 211, VICH GL18, and product-specific stability evaluation under VICH GL3. This presentation is not sterile; endotoxin control is nonetheless monitored at ≤ 5 EU/mL to avoid pyrogenic reactions after oral drench administration. Batch stability is tied to the absence of free water at the API surface; the propylene glycol fraction must not fall below 25% v/v or the API may precipitate at 4°C. The solution is filled into 1 L, 5 L, and 10 L high-density polyethylene containers with tamper-evident closures, and labelled with a maximum drench volume of 60 mL per adult bovine. The product must not be diluted in metal troughs because the API forms insoluble complexes with ferric ions at pH above 6.0. For liquid feed mixing into calf milk replacer, the drench solution is mixed at 20 mL per 100 L of prepared milk replacer, yielding a final concentration of 10 mg/L.